Autor segons l'article: Masana L; Ibarretxe D; Plana N
Departament: Medicina i Cirurgia
Autor/s de la URV: Ibarretxe Gerediaga, Daiana / Masana Marín, Luis / Plana Gil, Núria
Paraules clau: Very-low levels Statins Safety Pcsk9 inhibitors Metaanalysis Lipid-lowering combination therapy High-risk Fenofibrate therapy Ezetimibe Evolocumab Efficacy Density-lipoprotein cholesterol Cardiovascular prevention Cardiovascular outcomes Association pcsk9 inhibitors lipid-lowering combination therapy ezetimibe cardiovascular prevention
Resum: © 2020, The Author(s). Purpose of Review: The aim of this report is to review the scientific evidence supporting that lipid lowering therapy (LLT), beyond statins, reduces cardiovascular risk; therefore, treatment strategies based on lipid-lowering drug combination should be implemented. Recent Findings: A strong scientific body of evidence supports the effect of statins on cardiovascular risk reduction. Recent trials using non-statin LLT, ezetimibe, and PCSK9 inhibitors have provide scientific evidence about their impact on cardiovascular prevention. Current clinical guidelines still recommend using high-intensity statin monotherapy before considering combination therapy. Summary: The causal effect of LDL-C on atherosclerosis is well established. Moreover, new RCT, meta-analysis, and Mendelian randomization data, support that the main determinant of risk reduction is the absolute LDL reduction regardless of LLT. Accordingly, the “high-intensity statin therapy” concept should be substituted by “high-intensity lipid lowering therapy.” Combination therapy must become the standard of care of hypercholesterolemia treatment.
Àrees temàtiques: Saúde coletiva Medicina ii Medicina i Cardiology and cardiovascular medicine Cardiac & cardiovascular systems
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 15343170
Adreça de correu electrònic de l'autor: daiana.ibarretxe@urv.cat nuria.plana@urv.cat luis.masana@urv.cat
Identificador de l'autor: 0000-0002-4231-7618 0000-0002-0789-4954
Data d'alta del registre: 2023-02-19
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://link.springer.com/article/10.1007/s11886-020-01326-w
Referència a l'article segons font original: Current Cardiology Reports. 22 (8): 66-
Referència de l'ítem segons les normes APA: Masana L; Ibarretxe D; Plana N (2020). Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy. Current Cardiology Reports, 22(8), 66-. DOI: 10.1007/s11886-020-01326-w
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
DOI de l'article: 10.1007/s11886-020-01326-w
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2020
Tipus de publicació: Journal Publications
Repositori URV